Api Details

Linagliptin is an oral antidiabetic medication used as an Active Pharmaceutical Ingredient (API) for managing type 2 diabetes mellitus. It belongs to the class of dipeptidyl peptidase-4 (DPP-4) inhibitors, which work by increasing the levels of incretin hormones. These hormones enhance insulin secretion and decrease glucagon production in a glucose-dependent manner, leading to improved blood glucose control. Linagliptin is characterized by its long half-life, allowing for once-daily dosing without dose adjustments in renal or hepatic impairment. It is well-tolerated with a low risk of hypoglycemia and weight gain, making it a suitable option for many patients with type 2 diabetes.